Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methadone is a synthetic opioid used primarily for the treatment of opioid use disorder (OUD) and as an analgesic for severe pain. It is a long-acting full agonist at the µ-opioid receptor and also acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. Methadone reduces opioid cravings and withdrawal symptoms without producing the euphoria associated with other opioids. It can be administered orally or by injection but is most commonly given in liquid or tablet form for daily use in OUD treatment programs. Developed in Germany in the late 1930s by Gustav Ehrhart and Max Bockmühl, it was approved for medical use in 1947 and has since become a key component of medication-assisted therapy for addiction recovery[2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methadone.